TIminer integrates state-of-the-art bioinformatics tools to analyze single-sample RNA-seq data and somatic DNA mutations to characterize the tumor-immune interface including: (i) genotyping of HLAs from NGS data, (ii) prediction of tumor neoantigens using mutation data and HLA types, (iii) characterization of tumor-infiltrating immune cells from bulk RNA-seq data; and (iv) quantification of tumor immunogenicity from expression data. Here, HLA-S is linked to neoplasm.